[go: up one dir, main page]

MX2011011281A - Compuesto de carbinol que tiene un enlazante heterociclico. - Google Patents

Compuesto de carbinol que tiene un enlazante heterociclico.

Info

Publication number
MX2011011281A
MX2011011281A MX2011011281A MX2011011281A MX2011011281A MX 2011011281 A MX2011011281 A MX 2011011281A MX 2011011281 A MX2011011281 A MX 2011011281A MX 2011011281 A MX2011011281 A MX 2011011281A MX 2011011281 A MX2011011281 A MX 2011011281A
Authority
MX
Mexico
Prior art keywords
sup
sub
group
carbinol compound
lxrî2
Prior art date
Application number
MX2011011281A
Other languages
English (en)
Inventor
Takayuki Matsuda
Kimiyuki Shibuya
Minoru Koura
Hisashi Sumida
Yuichiro Watanabe
Takashi Enomoto
Sayaka Kurobuchi
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2011011281A publication Critical patent/MX2011011281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporciona un agonista novedoso de LXRß, útil como un agente preventivo y/o terapéutico para la aterosclerosis; arteriosclerosis, tales como aquélla que resultan de la diabetes; dislipidemia; hipercolesterolemia; enfermedades relacionadas con los lípidos; enfermedades inflamatorias que son causadas por citocinas inflamatorias; enfermedades de la piel tales como enfermedades alérgicas de la piel; diabetes o enfermedad de Alzheimer; es un compuesto de carbinol representado por la siguiente fórmula general (I) o sal del mismo, o su solvato:(ver fórmula (I)) (en donde, cada V y W muestran, de manera independiente, N o C-R7 cada X y Y muestran, de manera independiente, CH2, C=O, SO2, etc; Z muestra CH o N; cada R1, R2 y R7 muestran, de manera independiente, un átomo de hidrógeno, un grupo alquilo de C1-8, etc.; R3 muestra un grupo alquilo de C1-8 R4 muestra un grupo arilo de C6-10 sustituido opcionalmente o un grupo heterocíclico de 5 a 11 miembros sustituido opcionalmente; R5 y R6 muestran un átomo de hidrógeno, etc.; L muestra una cadena de alquilo de C1-8 sustituido opcionalmente con un grupo oxo, etc.; y n muestra cualquier entero de 0 a 2).
MX2011011281A 2009-04-29 2010-04-28 Compuesto de carbinol que tiene un enlazante heterociclico. MX2011011281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17369009P 2009-04-29 2009-04-29
PCT/JP2010/003039 WO2010125811A1 (ja) 2009-04-29 2010-04-28 ヘテロ環リンカーを有するカルビノール化合物

Publications (1)

Publication Number Publication Date
MX2011011281A true MX2011011281A (es) 2012-02-22

Family

ID=43030853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011281A MX2011011281A (es) 2009-04-29 2010-04-28 Compuesto de carbinol que tiene un enlazante heterociclico.

Country Status (15)

Country Link
US (1) US8551985B2 (es)
EP (1) EP2426113B1 (es)
JP (1) JP5774984B2 (es)
KR (1) KR101671046B1 (es)
CN (1) CN102438991B (es)
AU (1) AU2010243044C1 (es)
BR (1) BRPI1016232A2 (es)
CA (1) CA2759859C (es)
EA (1) EA201171167A1 (es)
IL (1) IL215229A0 (es)
MX (1) MX2011011281A (es)
NZ (1) NZ595910A (es)
TW (1) TW201043613A (es)
WO (1) WO2010125811A1 (es)
ZA (1) ZA201107617B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015029447A1 (ja) * 2013-08-30 2017-03-02 興和株式会社 光学活性カルビノール化合物の製造方法
JPWO2015037243A1 (ja) * 2013-09-12 2017-03-02 興和株式会社 光学活性ヒダントイン化合物の製造方法
EP3083602A1 (en) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
US10239849B2 (en) 2015-11-12 2019-03-26 Merck Sharp & Dohme Corp. Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
KR102762339B1 (ko) * 2019-01-23 2025-02-05 현대자동차주식회사 리튬 이차전지용 전해액, 이를 포함하는 리튬 이차전지
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof
CN111269134B (zh) * 2020-04-01 2022-09-20 九江中星医药化工有限公司 一种苯甘氨酸及其衍生物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
EP1318976B1 (en) 2000-09-18 2004-11-24 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
AU2003223340A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Certain pharmaceutically useful substituted aminoalkyl heterocycles
EP1534696A4 (en) * 2002-07-25 2010-04-07 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDO MINIIDES
EP1407774A1 (en) 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
WO2004072046A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivatives and their use for modulation of lxr activity
WO2005023188A2 (en) 2003-09-03 2005-03-17 Smithkline Beecham Corporation Compounds and methods
SV2005001973A (es) 2003-12-12 2005-11-04 Wyeth Corp Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
PL1732892T3 (pl) 2004-03-26 2009-03-31 Hoffmann La Roche Tetrahydrokarbazole i pochodne
CA2581945C (en) 2004-10-01 2011-01-18 Henrietta Dehmlow Hexafluoroisopropanol substituted ether derivatives
JP5159633B2 (ja) * 2006-11-30 2013-03-06 興和株式会社 置換カルビノール化合物
TW200922582A (en) * 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
CN102105452A (zh) 2008-05-29 2011-06-22 兴和株式会社 具有环状连接基的取代甲醇化合物

Also Published As

Publication number Publication date
US8551985B2 (en) 2013-10-08
CA2759859C (en) 2017-02-07
JPWO2010125811A1 (ja) 2012-10-25
BRPI1016232A2 (pt) 2023-04-11
AU2010243044B2 (en) 2015-07-30
KR101671046B1 (ko) 2016-10-31
AU2010243044C1 (en) 2016-08-25
JP5774984B2 (ja) 2015-09-09
EA201171167A1 (ru) 2012-06-29
CN102438991A (zh) 2012-05-02
CN102438991B (zh) 2015-08-26
EP2426113B1 (en) 2013-11-06
AU2010243044B8 (en) 2015-08-13
TW201043613A (en) 2010-12-16
EP2426113A1 (en) 2012-03-07
CA2759859A1 (en) 2010-11-04
US20100280013A1 (en) 2010-11-04
ZA201107617B (en) 2012-08-29
AU2010243044A8 (en) 2015-08-13
KR20120027164A (ko) 2012-03-21
EP2426113A4 (en) 2012-11-07
NZ595910A (en) 2013-06-28
AU2010243044A1 (en) 2011-11-10
IL215229A0 (en) 2011-12-29
WO2010125811A1 (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
MX2013002558A (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
MY169043A (en) New dihydroquinoline-2-one derivatives
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
MY152114A (en) Novel pyrazole-4-n-alkoxycarboxamides as microbiocides
EP2597088A4 (en) P2X4 Receptor Antagonists
SMT201300085B (it) Composti di pirrolo
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
NO20083408L (no) Korrosjonsinhibitorer som har okt biologisk nedbrytbarhet og redusert giftighet
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
WO2008136444A1 (ja) 縮合複素環誘導体
MX2010006787A (es) Análogos halogenados de agentes anti-fibroticos.
ATE478054T1 (de) Benzimidazolderivate
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体
MX2010001566A (es) Derivado de aminopirazolamida.
MX2012001155A (es) 2-(3-alquiltiobenzoil)ciclohexanodionas y su uso como herbicidas.
UA101018C2 (ru) Пирролопиримидинкарбоксамиды
PH12013501840A1 (en) Nitrogen-containing saturated heterocyclic compound
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
TN2013000439A1 (en) Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives

Legal Events

Date Code Title Description
FG Grant or registration